Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Department of Internal Medicine, Clinical Cancer Genetics Program, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
Hum Pathol. 2023 Jul;137:1-9. doi: 10.1016/j.humpath.2023.04.001. Epub 2023 Apr 6.
Mismatch repair (MMR) protein-deficient non-neoplastic colonic crypts and endometrial glands (dMMR crypts and glands) have been reported as a unique marker of underlying Lynch syndrome (LS). However, no large studies have directly compared the frequency of detection in cases with double somatic (DS) MMR mutations. We retrospectively analyzed 42 colonic resection specimens (24 LS and 18 DS) and 20 endometrial specimens (9 LS and 11 DS), including 19 hysterectomies and 1 biopsy for dMMR crypts and glands. All specimens were from patients with known primary cancers, including colonic adenocarcinomas and endometrial endometrioid carcinomas (including 2 mixed carcinomas). Four blocks of normal mucosa away from the tumor were selected from most cases, as available. MMR immunohistochemistry specific to the primary tumor mutations was analyzed. dMMR crypts were found in 65% of LS and 0% of DS MMR-mutated colonic adenocarcinomas (P < .001). Most dMMR crypts were detected in the colon (12 of 15) compared to the ileum (3 of 15). dMMR crypts showed single and grouped losses of MMR immunohistochemical expression. dMMR glands were found in 67% of LS and 9% (1 of 11) of DS endometrial cases (P = .017). Most dMMR glands were found in the uterine wall, with 1 LS and 1 DS case exhibiting dMMR glands in the lower uterine segment. Most cases exhibited multifocal and grouped dMMR glands. No morphologic atypia was identified in dMMR crypts or glands. Overall, we demonstrate that dMMR crypts and glands are highly associated with underlying LS, while being rarer in those with DS MMR mutations.
错配修复(MMR)蛋白缺陷的非肿瘤性结肠隐窝和子宫内膜腺体(dMMR 隐窝和腺体)已被报道为潜在林奇综合征(LS)的独特标志物。然而,尚无大型研究直接比较具有双体细胞(DS)MMR 突变的病例中检测到的频率。我们回顾性分析了 42 例结肠切除标本(24 例 LS 和 18 例 DS)和 20 例子宫内膜标本(9 例 LS 和 11 例 DS),包括 19 例子宫切除术和 1 例活检用于检测 dMMR 隐窝和腺体。所有标本均来自已知原发性癌症患者,包括结肠腺癌和子宫内膜子宫内膜样癌(包括 2 例混合癌)。大多数情况下,从大多数病例中选择了远离肿瘤的 4 块正常黏膜组织作为对照。分析了针对原发性肿瘤突变的 MMR 免疫组织化学。在 LS 中发现了 65%的 dMMR 隐窝和 0%的 DS MMR 突变的结肠腺癌(P<.001)。与回肠(15 例中的 3 例)相比,大多数 dMMR 隐窝在结肠(15 例中的 12 例)中被检测到。dMMR 隐窝显示 MMR 免疫组织化学表达的单一和分组丢失。在 LS 中发现了 67%的 dMMR 腺体和 9%(11 例中的 1 例)的 DS 子宫内膜病例(P=.017)。大多数 dMMR 腺体位于子宫壁,1 例 LS 和 1 例 DS 病例在子宫下段发现 dMMR 腺体。大多数病例表现为多灶性和分组性 dMMR 腺体。在 dMMR 隐窝或腺体中未发现形态异常。总体而言,我们证明 dMMR 隐窝和腺体与潜在的 LS 高度相关,而在具有 DS MMR 突变的患者中则更为罕见。